Pressroom

Trending Topics

 

Check out the latest cancer-related news and also see who is readily available to offer reliable information, expert commentary, and reaction to today's headlines.
Contact a media coordinator

Experts at Memorial Sloan Kettering Cancer Center (MSK) have identified genome doubling in cancer and have correlated it to a worse prognosis across cancer types. Using MSK-IMPACT™ to analyze matched tumor and normal DNA, MSK researchers were able to identify an abnormality in tumors known as genome doubling. This doubling occurs in 28 percent of all cancers and could have significant implications for treatment options in the future.
Monday, July 16, 2018
 
Drug resistance is a formidable challenge in cancer treatment. A drug called enasidenib (Idhifa®) was approved by the US Food and Drug Administration last year for the treatment of people with a form of acute myeloid leukemia (AML) that’s driven by a mutation in the gene IDH2. About 15 percent of people with AML have this mutation. Research led by Memorial Sloan Kettering Cancer Center (MSK) reports that people who take enasidenib can develop resistance to it — in a way never seen before. Enasidenib works differently than most cancer drugs. Rather than killing leukemia cells, it turns them into normal blood cells. The discovery of this unique resistence may lead to more-precise treatments for people with AML in the future.
Thursday, July 5, 2018
 
Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal of Medicine (NEJM). In the comprehensive review article, Drs. Sadelain and June highlight the emerging immunotherapy treatment for hematologic cancers known as CAR T cells, which was developed at MSK. The paper is the first in a series being published by NEJM. Known as Frontiers in Medicine, it will showcase ways that new technologies are influencing contemporary medicine and science.
Wednesday, July 4, 2018
 

See all trending topics
 

Press Releases

 

Pediatric surgeon J. Ted Gerstle, MD, FACS, FRCS, has been named the new Chief of the Pediatric Surgery Service in the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK).
Thursday, July 12, 2018
 
Memorial Sloan Kettering Cancer Center (MSK) has announced that Kreg Koford has been named MSK’s Senior Vice President of Supply Chain and Sustaining Care Services. Mr. Koford assumes his new role at MSK on July 9, 2018.
Tuesday, July 10, 2018
 
After more than two decades of providing outstanding cancer care to the people of New Jersey, Memorial Sloan Kettering announced today that its newest outpatient treatment center, in Bergen County, will welcome new patients in the coming weeks. In recognition of its debut, MSK’s leadership, joined by members of the community and local elected officials, gathered at the Montvale site to unveil MSK Bergen, a sleek, modern, technology-filled 110,000-plus-square-foot clinical program located on Summit Avenue, mere minutes from the Garden State Parkway.
Monday, June 25, 2018
 

See all press releases
 

On Our Blog

 

FINDING
MSK researchers have found that a genetic state in tumors called whole-genome doubling is connected with worse outcomes for people with cancer.
Wednesday, July 18, 2018
 
IN THE LAB
New drugs are being developed that target part of the process to make proteins.
Wednesday, July 18, 2018
 
IN THE CLINIC
If you’ve been treated for soft tissue sarcoma, a recurrence may be a big concern for you. Here’s what MSK’s sarcoma experts think you should know about the disease coming back.
Tuesday, July 17, 2018
 

See all blog posts
 

Media Coverage

 

MSK Bergen, the latest satellite center of one of the nation’s top-ranked cancer hospitals, is opening soon for outpatient care in Montvale, providing new treatment options for North Jersey patients who face the disease. MSK’s Matthew Matasar and Courtney Nowak are featured.
Monday, June 25, 2018
 
Exercise could improve the life expectancy of adults who survive cancer as children, even if the activity begins years after treatments end, according to an inspiring new study. But the study also finds that many survivors rarely, if ever, move much. Corresponding author MSK’s Lee Jones is highlighted.
Wednesday, June 20, 2018
 
For adult survivors of childhood cancer, vigorous exercise in early adulthood is associated with reduced risk of mortality, according to a study published online June 3 in JAMA Oncology. MSK’s Jessica Scott and colleagues conducted a multicenter cohort analysis among 15,450 adult cancer survivors diagnosed before age 21 years from pediatric tertiary hospitals.
Wednesday, June 13, 2018
 

See all media coverage
 

If you wish to contact MSK about a marketing or advertising related opportunity, or are looking for additional information about our ad campaign, please email us at marketing@mskcc.org.

For Journalists

Jeanne D'Agostino
Director, Media and Public Relations
 
Emily O'Donnell
Media Relations Manager, Surgery
 
Courtney Nowak
Media Relations Manager, Regional Care Network
 
Caitlin Hool
Senior Manager, Media Relations and Partnerships
 
Nicole H. McNamara
Senior Media Strategist
 
Rebecca Williams
Media Strategist
 
For press inquiries, our Media Staff are available by calling 646-227-3573 or by dialing the numbers above. Our office hours are Monday - Friday, 9:00 AM to 5:00 PM.
 
After hours, please contact the hospital's page operator at 212-639-7900 and ask for the Public Affairs representative on-call.

Live and Remote Broadcast Capabilities

Our experts can offer live broadcast interviews using the on-site studio system. To book an expert interview using our on-site broadcast studio contact our Media Staff.